Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

Video

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Daniel J. George, MD, professor of Medicine, professor in Surgery, Duke Cancer Institute, discusses the use of niraparib (Zejula) for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA and ATM mutations.

The phase 2 Galahad trial (NCT02854436) evaluated niraparib in patients with a documented biallelic DNA-repair anomaly, including those with BRCA and ATM mutations, among other defects, George explains.

Niraparib demonstrated a high clinical response rate in this patient population, George continues. Additionally, both the objective response rate and duration of response were beneficial, George concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH